{"pmid":32396137,"title":"Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.","text":["Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.","Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories.","Clin Chem Lab Med","Lippi, Giuseppe","Adeli, Khosrow","Ferrari, Maurizio","Horvath, Andrea R","Koch, David","Sethi, Sunil","Wang, Cheng-Bin","32396137"],"abstract":["Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Adeli, Khosrow","Ferrari, Maurizio","Horvath, Andrea R","Koch, David","Sethi, Sunil","Wang, Cheng-Bin"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396137","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1515/cclm-2020-0633","keywords":["covid-19","sars-cov-2","biosafety","coronavirus disease 2019","laboratory"],"topics":["Prevention"],"weight":1,"_version_":1666627827822231552,"score":9.490897,"similar":[{"pmid":32459192,"title":"Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","text":["Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis.","Clin Chem Lab Med","Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow","32459192"],"abstract":["The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis."],"journal":"Clin Chem Lab Med","authors":["Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459192","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1515/cclm-2020-0722","keywords":["covid-19","sars-cov-2","biochemical monitoring","molecular testing","serology testing"],"topics":["Diagnosis"],"weight":1,"_version_":1667967698909265920,"score":322.36697},{"pmid":32242878,"title":"Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis.","text":["Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis.","Novel coronavirus infection [coronavirus disease 2019 (COVID-19)] has spread to more than 203 countries of various regions including Africa, America, Europe, South East Asia and Western Pacific. The WHO had declared COVID-19 as the global public health emergency and subsequently as pandemic because of its worldwide spread. It is now one of the top-priority pathogens to be dealt with, because of high transmissibility, severe illness and associated mortality, wide geographical spread, lack of control measures with knowledge gaps in veterinary and human epidemiology, immunity and pathogenesis. The quick detection of cases and isolating them has become critical to contain it. To meet the increasing demand of the diagnostic services, it is necessary to enhance and expand laboratory capabilities since existing laboratories cannot meet the emerging demand. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a BSL-2 (Biosafety Level 2) agent and needs to be handled in biosafety cabinet using standard precautions. This review highlights minimum requirements for the diagnostic laboratories opting testing of material for the diagnosis of COVID-19 and associated biorisk to the individuals and to the community.","Indian J Med Res","Mourya, Devendra T","Sapkal, Gajanan","Yadav, Pragya D","M Belani, Sujeet Kumar","Shete, Anita","Gupta, Nivedita","32242878"],"abstract":["Novel coronavirus infection [coronavirus disease 2019 (COVID-19)] has spread to more than 203 countries of various regions including Africa, America, Europe, South East Asia and Western Pacific. The WHO had declared COVID-19 as the global public health emergency and subsequently as pandemic because of its worldwide spread. It is now one of the top-priority pathogens to be dealt with, because of high transmissibility, severe illness and associated mortality, wide geographical spread, lack of control measures with knowledge gaps in veterinary and human epidemiology, immunity and pathogenesis. The quick detection of cases and isolating them has become critical to contain it. To meet the increasing demand of the diagnostic services, it is necessary to enhance and expand laboratory capabilities since existing laboratories cannot meet the emerging demand. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a BSL-2 (Biosafety Level 2) agent and needs to be handled in biosafety cabinet using standard precautions. This review highlights minimum requirements for the diagnostic laboratories opting testing of material for the diagnosis of COVID-19 and associated biorisk to the individuals and to the community."],"journal":"Indian J Med Res","authors":["Mourya, Devendra T","Sapkal, Gajanan","Yadav, Pragya D","M Belani, Sujeet Kumar","Shete, Anita","Gupta, Nivedita"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242878","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.4103/ijmr.IJMR_763_20","keywords":[" biosafety"," diagnosis"," infrastructure"," laboratories"," novel coronavirus","biorisk"],"locations":["America"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1666138492092022785,"score":280.45676},{"pmid":32275124,"title":"Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm.","text":["Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm.","The pandemic caused by severe acute respiratory syndrome coronavirus 2 heavily involves all those working in a laboratory. Samples from known infected patients or donors who are considered healthy can arrive, and a colleague might be asymptomatic but able to transmit the virus. Working in a clinical laboratory is posing several safety challenges. Few years ago, International Society for Advancement of Cytometry published guidelines to safely analyze and sort human samples that were revised in these days. We describe the procedures that we have been following since the first patient appeared in Italy, which have only slightly modified our standard one, being all human samples associated with risks. (c) 2020 International Society for Advancement of Cytometry.","Cytometry A","Cossarizza, Andrea","Gibellini, Lara","De Biasi, Sara","Lo Tartaro, Domenico","Mattioli, Marco","Paolini, Annamaria","Fidanza, Lucia","Bellinazzi, Caterina","Borella, Rebecca","Castaniere, Ivana","Meschiari, Marianna","Sita, Marco","Manco, Gianrocco","Clini, Enrico","Gelmini, Roberta","Girardis, Massimo","Guaraldi, Giovanni","Mussini, Cristina","32275124"],"abstract":["The pandemic caused by severe acute respiratory syndrome coronavirus 2 heavily involves all those working in a laboratory. Samples from known infected patients or donors who are considered healthy can arrive, and a colleague might be asymptomatic but able to transmit the virus. Working in a clinical laboratory is posing several safety challenges. Few years ago, International Society for Advancement of Cytometry published guidelines to safely analyze and sort human samples that were revised in these days. We describe the procedures that we have been following since the first patient appeared in Italy, which have only slightly modified our standard one, being all human samples associated with risks. (c) 2020 International Society for Advancement of Cytometry."],"journal":"Cytometry A","authors":["Cossarizza, Andrea","Gibellini, Lara","De Biasi, Sara","Lo Tartaro, Domenico","Mattioli, Marco","Paolini, Annamaria","Fidanza, Lucia","Bellinazzi, Caterina","Borella, Rebecca","Castaniere, Ivana","Meschiari, Marianna","Sita, Marco","Manco, Gianrocco","Clini, Enrico","Gelmini, Roberta","Girardis, Massimo","Guaraldi, Giovanni","Mussini, Cristina"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275124","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/cyto.a.24009","keywords":["covid-19","sars-cov-2","biosafety","coronavirus","cytokines","cytometry"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138491732361216,"score":210.23808},{"pmid":32488957,"title":"Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.","text":["Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.","In response to the recent COVID-19 pandemic, many laboratories are involved in research supporting SARS-CoV-2 vaccine development and clinical trials. Flow cytometry laboratories will be responsible for a large part of this effort by sorting unfixed antigen-specific lymphocytes. Therefore, it is critical and timely that we have an understanding of risk assessment and established procedures of infectious cell sorting. Here we present procedures covering the biosafety aspects of sorting unfixed SARS-CoV-2-infected cells and other infectious agents of similar risk level. These procedures follow the ISAC Biosafety Committee guidelines and were recently approved by the National Institutes of Health Institutional Biosafety Committee for sorting SARS-CoV-2-infected cells. (c) 2020 International Society for Advancement of Cytometry.","Cytometry A","Reifel, Kristen M","Swan, Brandon K","Jellison, Evan R","Ambrozak, David","Baijer, Jan","Nguyen, Richard","Monard, Simon","Lyon, Geoffrey","Fontes, Benjamin","Perfetto, Stephen P","32488957"],"abstract":["In response to the recent COVID-19 pandemic, many laboratories are involved in research supporting SARS-CoV-2 vaccine development and clinical trials. Flow cytometry laboratories will be responsible for a large part of this effort by sorting unfixed antigen-specific lymphocytes. Therefore, it is critical and timely that we have an understanding of risk assessment and established procedures of infectious cell sorting. Here we present procedures covering the biosafety aspects of sorting unfixed SARS-CoV-2-infected cells and other infectious agents of similar risk level. These procedures follow the ISAC Biosafety Committee guidelines and were recently approved by the National Institutes of Health Institutional Biosafety Committee for sorting SARS-CoV-2-infected cells. (c) 2020 International Society for Advancement of Cytometry."],"journal":"Cytometry A","authors":["Reifel, Kristen M","Swan, Brandon K","Jellison, Evan R","Ambrozak, David","Baijer, Jan","Nguyen, Richard","Monard, Simon","Lyon, Geoffrey","Fontes, Benjamin","Perfetto, Stephen P"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32488957","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cyto.a.24040","keywords":["covid-19","isac biosafety committee","sars-cov-2 cell sorting procedure","biosafety and cell sorting","coronavirus","infectious cell sorting"],"topics":["Prevention"],"weight":1,"_version_":1668892169400745984,"score":191.61778},{"pmid":32116147,"title":"Coronavirus disinfection in histopathology.","text":["Coronavirus disinfection in histopathology.","The 2019 Coronavirus epidemic, provisionally called 2019-nCoV, was first identified in Wuhan, China, in persons exposed to a seafood or wet market. There is an international push to contain the virus and prevent its spread. It is feasible that potentially infectious samples may be received in histopathology laboratories for diagnosis. This technical note presents disinfection procedures and histotechnology processes that should alleviate the risk of infection to laboratory staff. Using data obtained from similar coronaviruses, e.g. severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus. Formalin fixation and heating samples to 56oC, as used in routine tissue processing, were found to inactivate several coronaviruses and it is believed that 2019-nCoV would be similarly affected.","J Histotechnol","Henwood, Anthony F","32116147"],"abstract":["The 2019 Coronavirus epidemic, provisionally called 2019-nCoV, was first identified in Wuhan, China, in persons exposed to a seafood or wet market. There is an international push to contain the virus and prevent its spread. It is feasible that potentially infectious samples may be received in histopathology laboratories for diagnosis. This technical note presents disinfection procedures and histotechnology processes that should alleviate the risk of infection to laboratory staff. Using data obtained from similar coronaviruses, e.g. severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus. Formalin fixation and heating samples to 56oC, as used in routine tissue processing, were found to inactivate several coronaviruses and it is believed that 2019-nCoV would be similarly affected."],"journal":"J Histotechnol","authors":["Henwood, Anthony F"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32116147","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1080/01478885.2020.1734718","keywords":["coronavirus","sars-cov-2","biosafety","disinfection","histopathology laboratory","histotechnology"],"locations":["Wuhan","China","Formalin"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Sodium Hypochlorite","Formaldehyde","Ethanol"],"topics":["Prevention"],"weight":1,"_version_":1666138492835463168,"score":189.49294}]}